Skip to main content

Table 2 Distribution of cell cycle phases in vehicle-treated and ABT-737-treated thyroid carcinoma cells (24 h, 1 µM)

From: The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells

Cell line Treatment % subG1 % G1 % G2/M % S
ML1 (FTC) Untreated 0.39 ± 0.1 37.5 ± 2.1 30.5 ± 2.4 32.0 ± 2.2
24 h ABT-737 21.2 ± 2.9* 34.0 ± 3.1 21.5 ± 1.9* 44.5 ± 3.6*
FTC236 (FTC) Untreated 0.21 ± 0.1 48.5 ± 4.4 24.1 ± 1.6 27.4 ± 2.0
24 h ABT-737 18.8 ± 2.0* 41.6 ± 3.9 20.3 ± 2.6 38.1 ± 2.9*
BHT101 (PTC) Untreated 3.16 ± 2.8 65.1 ± 5.3 16.0 ± 1.7 18.9 ± 2.3
24 h ABT-737 54.8 ± 4.6* 42.6 ± 5.3* 16.1 ± 2.7 41.3 ± 5.0*
SW1736 (ATC) Untreated 1.52 ± 0.4 54.9 ± 5.4 15.2 ± 2.2 29.9 ± 2.6
24 h ABT-737 39.9 ± 5.9* 42.8 ± 4.5* 13.2 ± 1.2 44.0 ± 3.6*
HTh7 (ATC) Untreated 3.10 ± 0.2 60.1 ± 4.9 10.6 ± 0.8 29.3 ± 2.6
24 h ABT-737 11.1 ± 1.4* 59.6 ± 4.7 3.3 ± 0.4* 37.1 ± 2.6*
  1. Values for G1-, G2/M- and S-phase are determined for the living cells that were not included in the sub-G1-peak
  2. * Indicates significant change (p < 0.05, Student’s t test) compared to controls treated with vehicle